Peoples Bank OH cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,372 shares of the company’s stock after selling 238 shares during the period. Johnson & Johnson comprises about 1.0% of Peoples Bank OH’s investment portfolio, making the stock its 23rd biggest position. Peoples Bank OH’s holdings in Johnson & Johnson were worth $1,479,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Lincoln Capital Corp raised its holdings in Johnson & Johnson by 15.9% during the third quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock valued at $218,000 after acquiring an additional 183 shares during the period. Ieq Capital LLC raised its holdings in Johnson & Johnson by 5.1% during the third quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock valued at $20,912,000 after acquiring an additional 6,154 shares during the period. RFG Advisory LLC raised its holdings in Johnson & Johnson by 2.7% during the third quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock valued at $3,900,000 after acquiring an additional 594 shares during the period. Willis Investment Counsel raised its holdings in Johnson & Johnson by 0.4% during the fourth quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock valued at $58,097,000 after acquiring an additional 1,358 shares during the period. Finally, FDx Advisors Inc. raised its holdings in Johnson & Johnson by 0.3% during the third quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock valued at $8,237,000 after acquiring an additional 153 shares during the period. 67.94% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Stock Down 0.5 %
Shares of NYSE JNJ opened at $162.69 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The firm has a market capitalization of $423.69 billion, a price-to-earnings ratio of 34.04, a PEG ratio of 2.63 and a beta of 0.53. The stock has a 50 day moving average price of $157.49 and a 200 day moving average price of $166.96. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $186.69.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. The ex-dividend date is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a yield of 2.93%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio is currently 94.56%.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on the company. Atlantic Securities reduced their target price on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a report on Wednesday. UBS Group assumed coverage on Johnson & Johnson in a report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 1st. SVB Leerink reduced their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday, January 20th. Finally, Morgan Stanley boosted their price objective on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $173.00.
Insiders Place Their Bets
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.20% of the stock is owned by company insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 4/17 – 4/21
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation’s Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
